Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-trans retinoic acid plus ivosidenib for IDH1-mutated myelodysplastic syndrome
ChiCTR2600133928Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tretinoin and ivosidenib in myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete Response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tretinoinivosidenib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600133928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133928.